CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Cash flows from operating activities:
Net Income (Loss)	$ 29,821	$ (47,733)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Non-cash revenue from settlement of customer refund liability	(53,737)	0
Amortization of debt discount and issuance costs	180	194
Amortization of premium on short-term investments	0	(221)
Depreciation expense	391	487
Stock-based compensation expense	5,255	4,386
Non-cash lease expense	622	579
Loss from equity method investment	0	1,625
Loss on impairment of equity investment	74	675
Change in fair value of CVR liability	(374)	(2,180)
Change in fair value of convertible notes	0	(15,890)
Gain on sale of asset	(11,737)	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,896	276
Other noncurrent assets	116	386
Accounts payable	(2,110)	(1,043)
Operating lease liability	(612)	(1,542)
Accrued expenses and other current liabilities	(3,328)	(7,714)
Net cash used in operating activities	(33,543)	(67,715)
Cash flows from investing activities:
Purchases of property and equipment	0	(75)
Proceeds from sale of asset	7,000	0
Maturities of short-term investments	0	20,000
Net cash provided by investing activities	7,000	19,925
Cash flows from financing activities:
Proceeds from borrowings under loan and security agreement	0	7,000
Proceeds from issuance of common stock in pre-closing financing	0	42,000
Cash acquired in connection with reverse recapitalization	0	53,158
Payment of reverse recapitalization transaction costs	0	(8,714)
Principal payments on venture debt	(3,125)	0
Proceeds from exercise of common stock options	0	1,694
Net cash provided by (used in) financing activities	(3,125)	95,138
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	(29,668)	47,348
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	78,612	31,264
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	48,944	78,612
Supplemental disclosure of non-cash operating, investing and financing activities:
Interest payments on venture debt	961	856
Issuance of common stock to Amgen at fair value	1,263	0
Short Term Investments Acquired In reverse recapitalization	0	19,905
Issuance of CVR at fair value	$ 0	$ 180